<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758574</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15090058</org_study_id>
    <nct_id>NCT02758574</nct_id>
  </id_info>
  <brief_title>Standard vs. Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism</brief_title>
  <acronym>SUNSET sPE</acronym>
  <official_title>Comparison of Standard Catheter Directed Thrombolysis vs. Ultrasound Assisted Thrombolysis for Patients With Acute Submassive Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare standard catheter directed thrombolysis to ultrasound accelerated
      thrombolysis for the treatment of acute submassive pulmonary embolism (PE). The study
      population will include patients eligible for catheter directed thrombolysis (CDT) for
      submassive PE. Subjects will be randomized to, either, standard catheter-directed
      thrombolysis or ultrasound-accelerated thrombolysis (USAT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute pulmonary embolism (PE) carries a high morbidity and is the third-leading cause of
      cardiovascular mortality in the western world. It accounts for 5-10% of in-hospital deaths
      that for the United States translates to 200,000 deaths per year.1 Recent registries and
      cohort studies suggest that approximately 10% of all patients with acute PE die during the
      first 1 to 3 months after diagnosis. Studies that have observed survivors for &gt;3 months have
      reported an incidence of chronic thromboembolic pulmonary hypertension (CTEPH) 1-5% within
      2-3 years after PE.6-10 It is an incapacitating long-term complication of thromboembolic
      disease with a negative impact on the patient's quality of life and prognosis.

      The management acute PE is mainly guided by the acuity and severity of clinical presentation.
      Initial systemic anticoagulation (AC) is the standard of care and treatment is escalated
      based on the clinical presentation and patient characteristics that may stratify them at a
      higher mortality risk. The goals of therapy are to primarily prevent mortality, and
      secondarily potentially prevent late onset chronic thromboembolic pulmonary hypertension
      (CTEPH) and improve quality of life.

      Massive PE is defined as PE associated with sustained hemodynamic instability, whereas
      submassive PE (sPE) is defined as PE without hemodynamic instability but with abnormal right
      ventricular (RV) function and/or evidence of myocardial necrosis. It is notable that there is
      ongoing interest to accurately risk stratify sPE to identify the patients who are at
      increased risk of decompensating and/or dying. Clinical scores, imaging tests and biomarkers
      are under investigation, yet an ideal prognostic tool is still pending. A novel cardiac
      biomarker, heart-type fatty acid-binding protein (h-FABP), is emerging as a significant
      predictor of mortality in patients with submassive PE.

      Systemic intravenous thrombolysis is universally recommended by all guideline bodies for
      massive pulmonary embolism, but remains controversial for submassive PE. In the most recent
      metaanalysis, the subgroup analysis of 8 submassive PE trials (1993-2014, n=1775) showed that
      thrombolytic therapy was associated with a mortality reduction (1.39% vs 2.92%) but with an
      increase in major bleeding (7.74% vs 2.25%). These results were mainly driven by the largest
      randomized trial (PEITHO, 1006 patients) which compared a single, weight-adapted i.v. bolus
      of tenecteplase with standard anticoagulation.

      The recent development of catheter-directed therapies such as catheter-directed thrombolysis
      (CDT), ultrasound-accelerated thrombolysis (USAT), and pharmacomechanical or aspiration
      thrombectomy has introduced more tools for the treatment of acute PE. Proponents of these
      techniques suggest that they may provide a similar therapeutic benefit as systemic
      thrombolysis, while decreasing the dose of thrombolytic required and potentially decreasing
      the risk of adverse bleeding events. Both the American Heart Association and more recently
      European Society of Cardiology have acknowledged CDT as a viable treatment alternative for
      high risk acute sPE (echocardiographic RV dysfunction and elevated cardiac biomarkers), if
      appropriate expertise is available and particularly when the bleeding risk is high.

      Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter
      within the pulmonary arterial thrombus burden under angiographic guidance. Thrombolytic
      medications are slowly infused through the catheter, which is left in place for the duration
      of the treatment. USAT is a modification of this therapy utilizing a proprietary system of
      local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus,
      allowing deeper penetration of lytic medication.

      Several observational non-controlled series have demonstrated the efficacy of
      catheter-directed techniques in improving clinical and hemodynamic parameters and reducing
      clot burden while demonstrating a favorable safety profile. The ULTIMA trial was the first
      randomized controlled trial to include CDIs for sPE comparing standardized fixed-dose of USAT
      (10mg rtPA per lung over 15 hours) and AC to AC alone. In the USAT group, but not in the
      heparin group, the mean RV/LV ratio was significantly reduced at 24 hours, but became
      comparable between the two groups at 90 days. The RV systolic function was significantly
      improved in the USAT group vs. the heparin group at both 24 hours and 90 days. In both study
      groups minor bleeding complications were rare and there were no major bleeding complications.
      The SEATTLE II trial, a single-arm study evaluating the effectiveness of USAT, showed also an
      RV/LV ratio improvement at 48 hours.

      Limited data exists for comparing different catheter-directed therapies for acute PE. The
      majority of recent series for catheter-directed interventions utilize USAT exclusively;
      however there is limited comparative effectiveness data comparing this modality to standard
      multi-sidehole catheter infusion. Preliminary, non-controlled data are conflicting. One
      series by Lin and colleagues of 33 high-risk PE patients suggested benefit for USAT for
      angiographic clearance of thrombus burden with more bleeding events in the CDT group.31 Kuo
      and colleagues noted no difference in outcomes and treatment specifics between USAT and CDT
      in the recently published early results of a multicenter prospective registry. Our
      retrospective analysis of 63 patients suggests that there may be no difference between the
      two treatment modalities, demonstrating similar rates of outcomes such as survival,
      hemodynamic stabilization, and echocardiographic parameters in both groups with similar
      procedure length and lytic dose in the time-adjusted cohorts. Selection bias cannot be
      underestimated in all these studies.

      The expected benefit of USAT has been dependent on the device's ability to increase
      penetration of lytic into thrombus using high frequency, low power ultrasound, due to its
      reversible effects on fibrin dissociation. This benefit has been shown to result in faster
      thrombus clearance in selected vascular beds in some studies, such as the recently published
      DUET study comparing USAT and CDT in arterial occlusions. More rapid clearance of pulmonary
      thrombus by USAT compared to standard CDT may prove to be clinically and cost effective (e.g.
      via reduced length of ICU and hospital stay). Alternatively, if thrombus clearance is
      similar, the cost of USAT may exceed the cost of CDT (proprietary equipment and disposables),
      without offering any potential advantage. Evidence from the venous circulation, coming from
      the recent BERNUTIFUL trial demonstrated no difference in time to thrombus clearance in lower
      extremity deep venous thrombosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PE thrombus load reduction (CT obstruction index) from baseline to the termination of lysis</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>Any ischemic or hemorrhagic stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Any major bleeding event defined as hemorrhagic stroke, need to transfuse or need to intervene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Right Ventricular/Left Ventricular Diameter (ratio)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status (6 min walk test)</measure>
    <time_frame>12 months</time_frame>
    <description>6 min walk test (meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness analysis</measure>
    <time_frame>12 months</time_frame>
    <description>Quality Adjusted Life Years - Costs based on in-hospital resource utilization and out-of hospital care and follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic Tricuspid Annular Plane Systolic Excursion (cm)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Questionnaire SF36 (score)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Questionnaire PE QOL (score)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Questionnaire San Diego Shortness of Breath (score)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>CDT without ultrasound acceleration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Catheter-Directed Thrombolysis: Utilization of a standard infusion catheter, placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications to treat/dissolve pulmonary embolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CDT ultrasound accelerated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound Accelerated Catheter-Directed Thrombolysis: Utilization of an infusion catheter that incorporates an ultrasound emitting wire both placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications with the ultrasound emitting wire activated to treat/dissolve pulmonary embolus</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CDT without ultrasound acceleration</intervention_name>
    <description>A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus a standard infusion catheter will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus.</description>
    <arm_group_label>CDT without ultrasound acceleration</arm_group_label>
    <other_name>Standard CDT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CDT with ultrasound acceleration</intervention_name>
    <description>A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus an infusion catheter that incorporates an ultrasound emitting wire will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus. The wire will be connected to an ultrasound generating device.</description>
    <arm_group_label>CDT ultrasound accelerated</arm_group_label>
    <other_name>Ultrasound assisted CDT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria: Inclusion Criteria:

          -  Subject is eligible for catheter directed thrombolysis per the study protocol for
             submassive PE (CT or echocardiographic RV strain (defined as RV/LV ratio &gt;1) without
             persisting hypotension &lt;90mmHg or drop of systolic blood pressure by at least 40mm Hg
             for at least 15 minutes with signs of end-organ hypoperfusion (cold extremities or low
             urinary output &lt;30 mL/h or mental confusion) and without the need of catecholamine
             support or cardiopulmonary resuscitation).

        Exclusion Criteria:

          -  pregnancy;

          -  index PE symptom duration &gt;14 days;

          -  high bleeding rsk (any prior intracranial hemorrhage,

          -  known structural intracranial cerebrovascular disease or neoplasm,

          -  ischemic stroke within 3 months,

          -  suspected aortic dissection, active bleeding or bleeding diathesis,

          -  recent spinal or cranial/brain surgery,

          -  recent closed-head or facial trauma with bony fracture or brain injury);

          -  participation in any other investigational drug or device study;

          -  life expectancy &lt;90 days;

          -  inability to comply with study assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Efthymios Avgerinos, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Efthymios Avgerinos, M.D.</last_name>
    <phone>412-802-3036</phone>
    <email>avgerinose@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dragone Patricia, MSN</last_name>
    <phone>412-623-8452</phone>
    <email>dragpa@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Efthymios Avgerinos, MD</last_name>
      <phone>412-802-3036</phone>
      <email>avgerinose@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rabih Chaer, MD</last_name>
      <phone>412-802-3036</phone>
      <email>chaerra@upmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UPMC Mercy</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Singh, MD</last_name>
      <phone>412-623-8444</phone>
      <email>singhmj@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bryan Tillman, MD</last_name>
      <phone>412-623-1280</phone>
      <email>tillmanbw@upmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UPMC Passavant</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Redlinger, MD</last_name>
      <phone>412-802-3024</phone>
      <email>redlingerre@upmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kahn SR, Houweling AH, Granton J, Rudski L, Dennie C, Hirsch A. Long-term outcomes after pulmonary embolism: current knowledge and future research. Blood Coagul Fibrinolysis. 2014 Jul;25(5):407-15. doi: 10.1097/MBC.0000000000000070. Review.</citation>
    <PMID>24469387</PMID>
  </reference>
  <reference>
    <citation>Avgerinos ED, Chaer RA. Catheter-directed interventions for acute pulmonary embolism. J Vasc Surg. 2015 Feb;61(2):559-65. doi: 10.1016/j.jvs.2014.10.036. Epub 2014 Dec 16. Review.</citation>
    <PMID>25524824</PMID>
  </reference>
  <reference>
    <citation>Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistlethwaite P, Vedantham S, White RJ, Zierler BK; American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011 Apr 26;123(16):1788-830. doi: 10.1161/CIR.0b013e318214914f. Epub 2011 Mar 21. Erratum in: Circulation. 2012 Aug 14;126(7):e104. Circulation. 2012 Mar 20;125(11):e495.</citation>
    <PMID>21422387</PMID>
  </reference>
  <reference>
    <citation>Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e419S-e496S. doi: 10.1378/chest.11-2301. Erratum in: Chest. 2012 Dec;142(6):1698-1704.</citation>
    <PMID>22315268</PMID>
  </reference>
  <reference>
    <citation>Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k. doi: 10.1093/eurheartj/ehu283. Epub 2014 Aug 29. Erratum in: Eur Heart J. 2015 Oct 14;36(39):2666. Eur Heart J. 2015 Oct 14;36(39):2642.</citation>
    <PMID>25173341</PMID>
  </reference>
  <reference>
    <citation>Becattini C, Agnelli G, Pesavento R, Silingardi M, Poggio R, Taliani MR, Ageno W. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest. 2006 Jul;130(1):172-5.</citation>
    <PMID>16840398</PMID>
  </reference>
  <reference>
    <citation>Meyer G, Planquette B, Sanchez O. Long-term outcome of pulmonary embolism. Curr Opin Hematol. 2008 Sep;15(5):499-503. doi: 10.1097/MOH.0b013e3283063a51. Review.</citation>
    <PMID>18695374</PMID>
  </reference>
  <reference>
    <citation>Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004 May 27;350(22):2257-64.</citation>
    <PMID>15163775</PMID>
  </reference>
  <reference>
    <citation>Sanchez O, Trinquart L, Colombet I, Durieux P, Huisman MV, Chatellier G, Meyer G. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J. 2008 Jun;29(12):1569-77. doi: 10.1093/eurheartj/ehn208. Epub 2008 May 21. Review.</citation>
    <PMID>18495689</PMID>
  </reference>
  <reference>
    <citation>Guérin L, Couturaud F, Parent F, Revel MP, Gillaizeau F, Planquette B, Pontal D, Guégan M, Simonneau G, Meyer G, Sanchez O. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost. 2014 Sep 2;112(3):598-605. doi: 10.1160/TH13-07-0538. Epub 2014 Jun 5.</citation>
    <PMID>24898545</PMID>
  </reference>
  <reference>
    <citation>Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, Kumbhani DJ, Mukherjee D, Jaff MR, Giri J. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014 Jun 18;311(23):2414-21. doi: 10.1001/jama.2014.5990.</citation>
    <PMID>24938564</PMID>
  </reference>
  <reference>
    <citation>Fasullo S, Scalzo S, Maringhini G, Ganci F, Cannizzaro S, Basile I, Cangemi D, Terrazzino G, Parrinello G, Sarullo FM, Baglini R, Paterna S, Di Pasquale P. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci. 2011 Jan;341(1):33-9. doi: 10.1097/MAJ.0b013e3181f1fc3e.</citation>
    <PMID>20890176</PMID>
  </reference>
  <reference>
    <citation>Kline JA, Steuerwald MT, Marchick MR, Hernandez-Nino J, Rose GA. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest. 2009 Nov;136(5):1202-1210. doi: 10.1378/chest.08-2988. Epub 2009 Jun 19.</citation>
    <PMID>19542256</PMID>
  </reference>
  <reference>
    <citation>Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M; “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the &quot;MOPETT&quot; Trial). Am J Cardiol. 2013 Jan 15;111(2):273-7. doi: 10.1016/j.amjcard.2012.09.027. Epub 2012 Oct 24.</citation>
    <PMID>23102885</PMID>
  </reference>
  <reference>
    <citation>Ain DL, Jaff MR. Treatment of Submassive Pulmonary Embolism: Knowing When to be Aggressive and When to be Conservative. Curr Treat Options Cardiovasc Med. 2015 Jun;17(6):385. doi: 10.1007/s11936-015-0385-y.</citation>
    <PMID>25895738</PMID>
  </reference>
  <reference>
    <citation>Klok FA, Meyer G, Konstantinides S. Management of intermediate-risk pulmonary embolism: uncertainties and challenges. Eur J Haematol. 2015 Dec;95(6):489-97. doi: 10.1111/ejh.12612. Epub 2015 Jul 15. Review.</citation>
    <PMID>26109174</PMID>
  </reference>
  <reference>
    <citation>Weinberg I, Jaff MR. Treating large pulmonary emboli: do the guidelines guide us? Curr Opin Pulm Med. 2013 Sep;19(5):413-21. doi: 10.1097/MCP.0b013e3283642a63. Review.</citation>
    <PMID>23884294</PMID>
  </reference>
  <reference>
    <citation>Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014 Apr 10;370(15):1402-11. doi: 10.1056/NEJMoa1302097.</citation>
    <PMID>24716681</PMID>
  </reference>
  <reference>
    <citation>Engelberger RP, Kucher N. Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review. Eur Heart J. 2014 Mar;35(12):758-64. doi: 10.1093/eurheartj/ehu029. Epub 2014 Feb 3. Review.</citation>
    <PMID>24497337</PMID>
  </reference>
  <reference>
    <citation>Engelhardt TC, Taylor AJ, Simprini LA, Kucher N. Catheter-directed ultrasound-accelerated thrombolysis for the treatment of acute pulmonary embolism. Thromb Res. 2011 Aug;128(2):149-54. doi: 10.1016/j.thromres.2011.05.014. Epub 2011 Jun 8.</citation>
    <PMID>21641020</PMID>
  </reference>
  <reference>
    <citation>Kucher N, Boekstegers P, Müller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, Tebbe U, Horstkotte J, Müller R, Blessing E, Greif M, Lange P, Hoffmann RT, Werth S, Barmeyer A, Härtel D, Grünwald H, Empen K, Baumgartner I. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014 Jan 28;129(4):479-86. doi: 10.1161/CIRCULATIONAHA.113.005544. Epub 2013 Nov 13.</citation>
    <PMID>24226805</PMID>
  </reference>
  <reference>
    <citation>Kuo WT. Endovascular therapy for acute pulmonary embolism. J Vasc Interv Radiol. 2012 Feb;23(2):167-79.e4; quiz 179. doi: 10.1016/j.jvir.2011.10.012. Epub 2011 Dec 20. Review.</citation>
    <PMID>22192633</PMID>
  </reference>
  <reference>
    <citation>Kuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann LV. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol. 2009 Nov;20(11):1431-40. doi: 10.1016/j.jvir.2009.08.002. Review.</citation>
    <PMID>19875060</PMID>
  </reference>
  <reference>
    <citation>Weinberg I, Jaff MR. Accelerated thrombolysis for pulmonary embolism: will clinical benefit be ULTIMAtely realized? Circulation. 2014 Jan 28;129(4):420-1. doi: 10.1161/CIRCULATIONAHA.113.007132. Epub 2013 Nov 13.</citation>
    <PMID>24226804</PMID>
  </reference>
  <reference>
    <citation>Bagla S, Smirniotopoulos JB, van Breda A, Sheridan MJ, Sterling KM. Ultrasound-accelerated catheter-directed thrombolysis for acute submassive pulmonary embolism. J Vasc Interv Radiol. 2015 Jul;26(7):1001-6. doi: 10.1016/j.jvir.2014.12.017. Epub 2015 Feb 18.</citation>
    <PMID>25704224</PMID>
  </reference>
  <reference>
    <citation>George B, Wallace EL, Charnigo R, Wingerter KE, Kapadia P, Gurley JC, Smyth SS. A retrospective analysis of catheter-based thrombolytic therapy for acute submassive and massive pulmonary embolism. Vasc Med. 2015 Apr;20(2):122-30. doi: 10.1177/1358863X14568135.</citation>
    <PMID>25832600</PMID>
  </reference>
  <reference>
    <citation>McCabe JM, Huang PH, Riedl L, Eisenhauer AC, Sobieszczyk P. Usefulness and safety of ultrasound-assisted catheter-directed thrombolysis for submassive pulmonary emboli. Am J Cardiol. 2015 Mar 15;115(6):821-4. doi: 10.1016/j.amjcard.2014.12.050. Epub 2015 Jan 7.</citation>
    <PMID>25633189</PMID>
  </reference>
  <reference>
    <citation>Kuo WT, Banerjee A, Kim PS, DeMarco FJ Jr, Levy JR, Facchini FR, Unver K, Bertini MJ, Sista AK, Hall MJ, Rosenberg JK, De Gregorio MA. Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): Initial Results From a Prospective Multicenter Registry. Chest. 2015 Sep;148(3):667-673. doi: 10.1378/chest.15-0119.</citation>
    <PMID>25856269</PMID>
  </reference>
  <reference>
    <citation>Piazza G ET, Sterling KM, et al. A prospective, single-arm, multicenter trial of the ekosonic endovascular system with activase for acute pulmonary embolism (seattle II). American College of Cardiology 63rd Annual Scientific Meeting. 2014</citation>
  </reference>
  <reference>
    <citation>Wärntges S, Konstantinides SV. Progress in the management of acute pulmonary embolism. Curr Opin Pulm Med. 2015 Sep;21(5):417-24. doi: 10.1097/MCP.0000000000000196. Review.</citation>
    <PMID>26186247</PMID>
  </reference>
  <reference>
    <citation>Lin PH, Annambhotla S, Bechara CF, Athamneh H, Weakley SM, Kobayashi K, Kougias P. Comparison of percutaneous ultrasound-accelerated thrombolysis versus catheter-directed thrombolysis in patients with acute massive pulmonary embolism. Vascular. 2009 Nov-Dec;17 Suppl 3:S137-47. Erratum in: Vascular. 2010 Jan-Feb;18(1):62.</citation>
    <PMID>19919804</PMID>
  </reference>
  <reference>
    <citation>Liang NL, Avgerinos ED, Marone LK, Singh MJ, Makaroun MS, Chaer RA. Equivalent Outcomes Between Ultrasound-Assisted Thrombolysis and Standard Catheter-Directed Thrombolysis for the Treatment of Acute Pulmonary Embolism. J Vasc Surg Venous Lymphat Disord. 2015 Jan;3(1):120-1. doi: 10.1016/j.jvsv.2014.10.015. Epub 2014 Dec 15.</citation>
    <PMID>26993702</PMID>
  </reference>
  <reference>
    <citation>Schrijver AM, van Leersum M, Fioole B, Reijnen MM, Hoksbergen AW, Vahl AC, de Vries JP. Dutch randomized trial comparing standard catheter-directed thrombolysis and ultrasound-accelerated thrombolysis for arterial thromboembolic infrainguinal disease (DUET). J Endovasc Ther. 2015 Feb;22(1):87-95. doi: 10.1177/1526602814566578.</citation>
    <PMID>25775686</PMID>
  </reference>
  <reference>
    <citation>Engelberger RP, Spirk D, Willenberg T, Alatri A, Do DD, Baumgartner I, Kucher N. Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis. Circ Cardiovasc Interv. 2015 Jan;8(1). pii: e002027. doi: 10.1161/CIRCINTERVENTIONS.114.002027.</citation>
    <PMID>25593121</PMID>
  </reference>
  <reference>
    <citation>Qanadli SD, El Hajjam M, Vieillard-Baron A, Joseph T, Mesurolle B, Oliva VL, Barré O, Bruckert F, Dubourg O, Lacombe P. New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. AJR Am J Roentgenol. 2001 Jun;176(6):1415-20.</citation>
    <PMID>11373204</PMID>
  </reference>
  <reference>
    <citation>Mastora I, Remy-Jardin M, Masson P, Galland E, Delannoy V, Bauchart JJ, Remy J. Severity of acute pulmonary embolism: evaluation of a new spiral CT angiographic score in correlation with echocardiographic data. Eur Radiol. 2003 Jan;13(1):29-35. Epub 2002 Jun 19.</citation>
    <PMID>12541107</PMID>
  </reference>
  <reference>
    <citation>Gorkin L, Norvell NK, Rosen RC, Charles E, Shumaker SA, McIntyre KM, Capone RJ, Kostis J, Niaura R, Woods P, et al. Assessment of quality of life as observed from the baseline data of the Studies of Left Ventricular Dysfunction (SOLVD) trial quality-of-life substudy. Am J Cardiol. 1993 May 1;71(12):1069-73.</citation>
    <PMID>8475871</PMID>
  </reference>
  <reference>
    <citation>ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. Erratum in: Am J Respir Crit Care Med. 2016 May 15;193(10):1185.</citation>
    <PMID>12091180</PMID>
  </reference>
  <reference>
    <citation>Kennedy RJ, Kenney HH, Dunfee BL. Thrombus resolution and hemodynamic recovery using ultrasound-accelerated thrombolysis in acute pulmonary embolism. J Vasc Interv Radiol. 2013 Jun;24(6):841-8. doi: 10.1016/j.jvir.2013.02.023. Epub 2013 Apr 16.</citation>
    <PMID>23601295</PMID>
  </reference>
  <reference>
    <citation>Blinc A, Francis CW, Trudnowski JL, Carstensen EL. Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood. 1993 May 15;81(10):2636-43.</citation>
    <PMID>8490172</PMID>
  </reference>
  <reference>
    <citation>Francis CW, Blinc A, Lee S, Cox C. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol. 1995;21(3):419-24.</citation>
    <PMID>7645133</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Efthymios Avgerinos, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>acute pulmonary embolism</keyword>
  <keyword>submassive pulmonary embolism</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>catheter directed thrombolysis</keyword>
  <keyword>ultrasound assisted thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrinolytic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

